

# ValÃ©rie Vingtdeux

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9360053/publications.pdf>

Version: 2024-02-01

50  
papers

4,737  
citations

172207

29  
h-index

189595

50  
g-index

60  
all docs

60  
docs citations

60  
times ranked

9089  
citing authors

#	ARTICLE	IF	CITATIONS
1	AMP-activated Protein Kinase Signaling Activation by Resveratrol Modulates Amyloid- $\beta$ Peptide Metabolism. <i>Journal of Biological Chemistry</i> , 2010, 285, 9100-9113.	1.6	560
2	CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. <i>Nature</i> , 2013, 495, 223-226.	13.7	405
3	Massive CA1/2 Neuronal Loss with Intraneuronal and N-Terminal Truncated A $\beta$ 42 Accumulation in a Novel Alzheimer Transgenic Model. <i>American Journal of Pathology</i> , 2004, 165, 1289-1300.	1.9	375
4	Resveratrol mitigates lipopolysaccharide- and A $\beta$ -mediated microglial inflammation by inhibiting the TLR4/NF- $\kappa$ B/STAT signaling cascade. <i>Journal of Neurochemistry</i> , 2012, 120, 461-472.	2.1	363
5	A Polymorphism in CALHM1 Influences Ca <sup>2+</sup> Homeostasis, A $\beta$ Levels, and Alzheimer's Disease Risk. <i>Cell</i> , 2008, 133, 1149-1161.	13.5	310
6	Calcium signaling in neurodegeneration. <i>Molecular Neurodegeneration</i> , 2009, 4, 20.	4.4	258
7	AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. <i>Acta Neuropathologica</i> , 2011, 121, 337-349.	3.9	247
8	Novel synthetic small molecule activators of AMPK as enhancers of autophagy and amyloid- $\beta$ peptide degradation. <i>FASEB Journal</i> , 2011, 25, 219-231.	0.2	209
9	Therapeutic potential of resveratrol in Alzheimer's disease. <i>BMC Neuroscience</i> , 2008, 9, S6.	0.8	178
10	Alkalizing Drugs Induce Accumulation of Amyloid Precursor Protein By-products in Luminal Vesicles of Multivesicular Bodies. <i>Journal of Biological Chemistry</i> , 2007, 282, 18197-18205.	1.6	176
11	Inhibition of AMP-Activated Protein Kinase Signaling Alleviates Impairments in Hippocampal Synaptic Plasticity Induced by Amyloid $\beta$ . <i>Journal of Neuroscience</i> , 2014, 34, 12230-12238.	1.7	143
12	Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca <sup>2+</sup> regulation of neuronal excitability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1963-71.	3.3	132
13	AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. <i>Scientific Reports</i> , 2016, 6, 26758.	1.6	95
14	Potential Contribution of Exosomes to the Prion-Like Propagation of Lesions in Alzheimer's Disease. <i>Frontiers in Physiology</i> , 2012, 3, 229.	1.3	93
15	Down-Regulation of the Met Receptor Tyrosine Kinase by Presenilin-dependent Regulated Intramembrane Proteolysis. <i>Molecular Biology of the Cell</i> , 2009, 20, 2495-2507.	0.9	92
16	Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. <i>Neurobiology of Disease</i> , 2005, 20, 625-637.	2.1	82
17	Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. <i>Neurobiology of Disease</i> , 2007, 25, 686-696.	2.1	78
18	Identification and biology of $\beta$ -secretase. <i>Journal of Neurochemistry</i> , 2012, 120, 34-45.	2.1	77

#	ARTICLE	IF	CITATIONS
19	Small-Molecule Activators of AMP-Activated Protein Kinase (AMPK), RSVA314 and RSVA405, Inhibit Adipogenesis. <i>Molecular Medicine</i> , 2011, 17, 1022-1030.	1.9	75
20	AMP-Activated Protein Kinase Is Essential for the Maintenance of Energy Levels during Synaptic Activation. <i>iScience</i> , 2018, 9, 1-13.	1.9	59
21	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. <i>Molecular Medicine</i> , 2014, 20, 29-36.	1.9	55
22	Neuronal AMP-activated protein kinase hyper-activation induces synaptic loss by an autophagy-mediated process. <i>Cell Death and Disease</i> , 2019, 10, 221.	2.7	54
23	Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: Two individual consequences of CUG trinucleotide repeats. <i>Experimental Neurology</i> , 2008, 210, 467-478.	2.0	47
24	AMPK in Neurodegenerative Diseases. <i>Exs</i> , 2016, 107, 153-177.	1.4	38
25	CALHM1 controls the Ca <sup>2+</sup> -dependent MEK, ERK, RSK and MSK signaling cascade in neurons. <i>Journal of Cell Science</i> , 2013, 126, 1199-1206.	1.2	35
26	Chloroquine and Chloroquinoline Derivatives as Models for the Design of Modulators of Amyloid Peptide Precursor Metabolism. <i>ACS Chemical Neuroscience</i> , 2015, 6, 559-569.	1.7	35
27	CALHM1 ion channel elicits amyloid- $\beta^2$ clearance by insulin-degrading enzyme in cell lines and <i>in vivo</i> in the mouse brain. <i>Journal of Cell Science</i> , 2015, 128, 2330-2338.	1.2	32
28	Epstein-Barr Virus Protein EB2 Contains an N-Terminal Transferable Nuclear Export Signal That Promotes Nucleocytoplasmic Export by Directly Binding TAP/NXF1. <i>Journal of Virology</i> , 2009, 83, 12759-12768.	1.5	31
29	AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives. <i>Current Drug Targets</i> , 2016, 17, 890-907.	1.0	31
30	Protein Kinase CK2 Phosphorylation of EB2 Regulates Its Function in the Production of Epstein-Barr Virus Infectious Viral Particles. <i>Journal of Virology</i> , 2007, 81, 11850-11860.	1.5	30
31	CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice. <i>Scientific Reports</i> , 2016, 6, 24250.	1.6	30
32	Identification of potent small-molecule inhibitors of STAT3 with anti-inflammatory properties in RAW264.7 macrophages. <i>FEBS Journal</i> , 2012, 279, 3791-3799.	2.2	29
33	AMP-activated Protein Kinase Controls Immediate Early Genes Expression Following Synaptic Activation Through the PKA/CREB Pathway. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3716.	1.8	29
34	CALHM1 P86L Polymorphism Modulates CSF A $\beta^2$ Levels in Cognitively Healthy Individuals at Risk for Alzheimer's Disease. <i>Molecular Medicine</i> , 2011, 17, 974-979.	1.9	26
35	Response: CALHM1 Association with Alzheimer's Disease Risk. <i>Cell</i> , 2008, 135, 994-996.	13.5	25
36	Contribution of the Endosomal-Lysosomal and Proteasomal Systems in Amyloid- $\beta^2$ Precursor Protein Derived Fragments Processing. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 435.	1.8	24

#	ARTICLE	IF	CITATIONS
37	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. <i>Molecular Medicine</i> , 2013, 19, 29-36.	1.9	22
38	New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2019, 129, 217-233.	2.1	21
39	The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. <i>Journal of Biomedical Science</i> , 2019, 26, 89.	2.6	20
40	Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke. <i>Proteome Science</i> , 2014, 12, 24.	0.7	17
41	Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. <i>Neurobiology of Aging</i> , 2013, 34, 757-769.	1.5	16
42	A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect $\beta$ -secretase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 159, 104-125.	2.6	16
43	Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid- $\beta$ precursor protein. <i>Human Molecular Genetics</i> , 2011, 20, 2026-2036.	1.4	15
44	Postnatal neurodevelopmental expression and glutamate-dependent regulation of the ZNF804A rodent homologue. <i>Schizophrenia Research</i> , 2015, 168, 402-410.	1.1	12
45	Effect of the CALHM1 G330D and R154H Human Variants on the Control of Cytosolic Ca <sup>2+</sup> and A $\beta$ Levels. <i>PLoS ONE</i> , 2014, 9, e112484.	1.1	11
46	A Modification-Specific Peptide-Based immunization Approach Using CRM197 Carrier Protein: Development of a Selective Vaccine Against Pyroglutamate A $\beta$ Peptides. <i>Molecular Medicine</i> , 2016, 22, 841-849.	1.9	7
47	Study of AMPK-Regulated Metabolic Fluxes in Neurons Using the Seahorse XFe Analyzer. <i>Methods in Molecular Biology</i> , 2018, 1732, 289-305.	0.4	7
48	Gas1 Interferes with A $\beta$ PP Trafficking by Facilitating the Accumulation of Immature A $\beta$ PP in Endoplasmic Reticulum-Associated Raft Subdomains. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 127-135.	1.2	2
49	Letter to the Editor on "Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis". <i>Biochemical and Biophysical Research Communications</i> , 2010, 400, 452.	1.0	1
50	Contribution of Multivesicular Bodies to the Prion-Like Propagation of Lesions in Alzheimer's Disease. , 2011, , .		0